February 02, 2023
Pliant Therapeutics
Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
February 02, 2023
Magenta Therapeutics
Magenta Therapeutics to Explore Strategic Alternatives
January 27, 2023
Pliant Therapeutics
Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
January 25, 2023
Tango Therapeutics
Tango Therapeutics Announces FDA Clearance Of Investigational New Drug Application For TNG462; Provides Additional Business Updates